Breast Cancer Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Breast Cancer Pipeline Outlook
Key Takeaways from the Breast Cancer Pipeline Report
In July 2025, Merck Sharp & Dohme LLC announced a study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
In July 2025, Pfizer announced a clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer).
In July 2025, AstraZeneca conducted a study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
DelveInsight's Breast Cancer pipeline report depicts a robust space with 100+ Breast Cancer companies working to develop 120+ pipeline therapies for Breast Cancer treatment.
The leading Breast Cancer Companies such as Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
Promising Breast Cancer Pipeline Therapies such as Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment
Breast Cancer Emerging Drugs Profile
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of Breast Cancer.
HLX11: Shanghai Henlius Biotech
HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer.
Praluzatamab ravtansine: CytomX Therapeutics
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.
MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer.
DX126 262: Hangzhou DAC Biotech
DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.
Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight's detailed report now! @ New Breast Cancer Drugs
Breast Cancer Companies
Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others
Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Breast Cancer Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Breast Cancer Market Drivers and Barriers
Scope of the Breast Cancer Pipeline Report
Coverage- Global
Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Breast Cancer Executive Summary
Breast Cancer: Overview
Breast Cancer Pipeline Therapeutics
Breast Cancer Therapeutic Assessment
Breast Cancer– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
MCLA-128: Merus N.V.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DX126 262: Hangzhou DAC Biotech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
ES2B C001: ExpreS2ion Biotechnologies
Drug profiles in the detailed report…..
Inactive Products
Breast Cancer Companies
Breast Cancer Products
Breast Cancer Unmet Needs
Breast Cancer Market Drivers and Barriers
Breast Cancer Future Perspectives and Conclusion
Breast Cancer Analyst Views
Breast Cancer Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/breast-cancer-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
34 minutes ago
- Globe and Mail
Billionaires Sell Apple Stock and Buy a Stock-Split Stock Up 510% in the Last Decade
Key Points In the first quarter, billionaires David Shaw and Louis Bacon sold Apple and bought O'Reilly Automotive, a stock-split stock up 510% in the last decade. Apple is struggling to incorporate artificial intelligence into its business, and the company has gone seven-plus years without a groundbreaking new product. O'Reilly Automotive could be a winner as President Trump's tariffs encourage consumers to service older vehicles rather than purchasing new ones. 10 stocks we like better than Apple › The hedge fund billionaires listed below sold Apple (NASDAQ: AAPL) during the first quarter and bought O'Reilly Automotive (NASDAQ: ORLY), a company whose share price rocketed 510% over the last decade, leading to a 15-for-1 stock split in early June. David Shaw's D.E. Shaw & Co. sold 340,900 shares of Apple, trimming its stake by 6%. The hedge fund also added 19,000 shares of O'Reilly Automotive, though it remains a very small holding. Louis Bacon's Moore Capital Management sold 495,800 shares of Apple, cutting its stake 97%. The hedge fund also purchased 240 shares of O'Reilly Automotive, starting a very small position. Importantly, both hedge funds still have exposure to Apple, and neither has an especially large position in O'Reilly Automotive. But investors should still consider both trades for their own portfolios. Here's why. 1. Apple Apple has durable brand moat built on design expertise that spans hardware and software. The company once again led the market in smartphone revenue in the March quarter, and it posted double-digit sales growth in its services segment due to strength in advertising, the App Store, and cloud storage. But its overall performance was still uninspiring. Revenue rose 5% to $95 billion, and generally accepted accounting principles (GAAP) net income climbed 5% to $24.8 billion. Importantly, Apple has struggled to incorporate artificial intelligence (AI) into its business. Analysts thought the suite of generative AI features added last year (i.e., Apple Intelligence) would catalyze a massive iPhone upgrade cycle, but the consumer response has so far been underwhelming, perhaps because the company has repeatedly delayed highly anticipated AI upgrades to its digital assistant Siri. Apple's failure to monetize AI speaks to a larger problem: The company has seemingly lost its capacity for innovation. After a long stint of very successful product launches -- the iPhone in 2007, the iPad in 2010, the Apple Watch in 2015, and AirPods in 2017 -- Apple has now gone seven-plus years without a noteworthy new product. And its inability to capitalize on soaring demand for AI is a troubling continuation of that pattern. Wall Street expects Apple's earnings to increase at 11% annually over the next three years. That already makes the current valuation of 33 times earnings look expensive, but analysts may be overestimating. Apple's earnings compounded at less than 2% annually during the last three years despite the company repurchasing 8% of its outstanding shares. Put differently, had Apple not repurchased any stock during the last three years, earnings would have declined nearly 5% in that period. And with no clear catalysts on the horizon, earnings growth is likely to be meager in the coming years. Investors should avoid the stock right now, and shareholders with especially large positions should consider trimming. 2. O'Reilly Automotive O'Reilly Automotive is one of the largest specialty retailers of aftermarket automative parts, tools, equipment, and accessories. The company operates more than 6,400 stores across North America, serving both do-it-yourself (DIY) and professional customers. It also has a robust distribution network that allows "timely access to a broad range of products," which helps the company retain customers. Importantly, while O'Reilly will be impacted by tariffs on imported automobiles and parts, duties imposed by the Trump administration could actually be a net win for the company. That's because the 25% tax on imported automobiles will raise car prices, encouraging consumers to service older vehicles rather than purchasing new ones. Furthermore, the average interest rate on U.S. auto loans has almost doubled in the last four years. O'Reilly reported encouraging Q2 financial results. Revenue rose 6% to $4.5 billion, driven by 67 new store openings and 4.1% same-store sales growth. Meanwhile, GAAP earnings jumped 11% to $0.78 per diluted share, outpacing revenue growth because the company repurchased 6.8 million shares. Management also raised full-year guidance, such that earnings are forecast to increase 9% in 2025. Wall Street expects O'Reilly's earnings to increase at 10% annually during the next three to five years. That makes the current valuation of 36 times earnings look relatively expensive. Nevertheless, I think investors should consider buying a small position in this stock today. And if the share price declines, they should consider building a bigger position at a more reasonable valuation multiple. Should you invest $1,000 in Apple right now? Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
an hour ago
- Globe and Mail
The Best Artificial Intelligence (AI) Stock to Buy With the Market At All-Time Highs
Key Points Alphabet stock is still trading at a cheap multiple. It has many growth vectors to benefit from artificial intelligence. Margin can help the company's profits explode in the next few years. These 10 stocks could mint the next wave of millionaires › The S&P 500 keeps soaring to new highs, making it feel impossible to find a cheap large-cap stock to buy today. This is especially true in technology and artificial intelligence (AI). Stocks such as Nvidia and Microsoft have price-to-earnings (P/E) ratios approaching 40 or higher, making them risky for investors. Growth expectations are high for many companies, which can make it increasingly difficult to buy stocks for your investment portfolio, especially if you care about value investing. That isn't the case with every AI stock. Here's why Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL) is the one AI stock you can buy right now with stocks at all-time highs. Alphabet's matrix of growth Some pundits have deemed Alphabet -- parent company of Google -- an AI loser because of competition from ChatGPT. I think this underplays the big picture. Alphabet has perhaps the most to gain from AI through its various subsidiaries, while also employing the best data advantage of any big technology player because of all the user data from Google, YouTube, and other properties. AI is not going to eliminate Google Search -- it will take it to the next level. AI overviews are already growing like a weed for Google Search results, while the Gemini chatbot is helping with advanced conversational queries. An explosion in new AI technologies will greatly expand the addressable market for Google and its related properties. That's why revenue is growing at a 10% annual rate for Google Services, even though it generated $77 billion in revenue just in the first quarter. Another way Alphabet can benefit from AI demand is Google Cloud, which is growing revenue at an astonishing 28% year-over-year clip, and is close to surpassing $50 billion in annualized revenue (it may surpass that mark next quarter). AI workloads will need huge amounts of specialized computing power to function, which Google Cloud is set to provide. Let's not forget self-driving start-up Waymo, which is taking over the streets of America's big cities, using Alphabet's infrastructure, engineering, and AI expertise. It is an entire matrix of growth for Alphabet that can be supercharged by AI. Profit margin expansion? AI requires a lot of upfront spending on data centers and computer chips in order to train and operate. Alphabet is planning to spend $75 billion on capital expenditures in 2025, mostly related to AI. This will increase depreciation and require steady growth in order to get a return on this investment, which some investors are skeptical about. Google Cloud used to be unprofitable, but it posted an 18% operating margin last quarter, a number that can keep expanding as it reaches larger scale. Due to these factors plus better hiring efficiency employed by Alphabet coming out of the pandemic, I think Alphabet's profit margins are set to keep inching higher over the next few years. Its operating margin recently hit a record of 33%. With huge operating leverage on its fixed-cost investments, I think this figure can grow to 40% over the long term, which is similar to Microsoft. With revenue at $359 billion that could grow to $400 billion or even $500 billion within a decade, a 40% operating margin could help Alphabet grow its operating income to $200 billion within a few years. That would make it the most profitable company in the world. GOOG PE Ratio data by YCharts. Buybacks and a cheap stock With all the earnings flowing to its balance sheet, Alphabet is returning capital to shareholders through buybacks and dividends. It pays a dividend yielding 0.42% that is set to grow steadily, while shares outstanding have fallen by 12% in the last 10 years. Alphabet plans to keep repurchasing stock at these cheap prices. It has a P/E ratio of 21, which is the cheapest among the " Magnificent Seven" stocks. This is shocking to see, given how much Alphabet can benefit from AI and cloud computing growth. Add everything up, and Alphabet looks like a fantastic stock to buy today, even with the market at all-time highs. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,040%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
3 hours ago
- Globe and Mail
US-China trade talks: Can China reduce its export dependence?
BEIJING (AP) — China's high dependence on exports will likely be a key focus of a new round of U.S.-China trade talks this coming week in Stockholm, but a trade deal would not necessarily help Beijing to rebalance its economy. U.S. Treasury Secretary Scott Bessent has said he hopes the negotiations can take up this issue, along with China's purchases of oil from Russia and Iran, which undercut American sanctions on those two countries. Hopes rose for a breakthrough in talks after U.S. President Donald Trump announced deals with Japan, Indonesia and the Philippines this week. The U.S. wants China to do two things: Reduce what both the U.S. and the European Union see as excess production capacity in many industries, including steel and electric vehicles. And secondly, to take steps to increase spending by Chinese consumers so the economy relies more on domestic demand and less on exports. 'We could also discuss the elephant in the room, which is this great rebalancing that the Chinese need to do,' Bessent told financial news network CNBC. He said China's share of global manufacturing exports at nearly 30%, 'can't get any bigger, and it should probably shrink.' China is tackling the same issues — for domestic reasons The issues are not new, and China has been working to address them for years, more for domestic reasons than to reduce its trade surpluses with the U.S. and other countries. Bessent's predecessor as treasury secretary, Janet Yellen, made industrial policy a focus of a trip to China last year. She blamed government subsidies for flooding the global market with 'artificially cheap Chinese products.' The European Union, whose top leaders met their Chinese counterparts in Beijing on Thursday, has cited subsidies to justify EU tariffs on electric vehicles made in China. In the 1980s, the U.S. pressured Japan to boost consumer spending when American manufacturing was overwhelmed by exports from the likes of Toyota and Sony. Economists have long argued that China likewise needs to transform into a more consumer-driven economy. Consumer spending accounts for less than 40% of China's economy, versus close to 70% in the United States and about 54% in Japan. Chinese leaders have spoken about both factory overcapacity and weak consumer spending as long-term problems and have sought over the past 20 years to find ways to rebalance the economy away from export manufacturing and massive investments in dams, roads, railways and other infrastructure. Fierce price wars have prompted critical reports in official media saying that companies are 'racing to the bottom,' skimping on quality and even safety to reduce costs. With strong government support, they've also expanded overseas, where they can charge higher prices but still undercut local competitors, creating a political backlash. Economists say China needs a consumer-driven economy All that competition and price cutting has left China battling deflation, or falling prices. When companies receive less for their products, they tend to invest less. That can lead to job cuts and lower wages, sapping business activity and spending power — contrary to the long-term goal of increasing the share of consumer spending in driving overall growth. To counter that, the government is spending billions on rebates and subsidies for people who trade in their cars or appliances for new ones. But acknowledging a problem and solving it are two different things. Economists say more fundamental changes are needed to boost consumption and rein in overcapacity. Such changes can only come incrementally over time. Private Chinese companies and foreign-invested companies create the most jobs, but they've suffered from swings in policy and pressures from the trade war, especially since the pandemic. Demographic changes are another challenge as China's population shrinks and ages. Many experts advocate expanding China's social safety net, health insurance, pensions and other support systems, so that people would feel freer to spend rather than save for a medical emergency or retirement. Yan Se, an economist at Peking University's Guanghua School of Management, warned at a recent forum that deflation will become a long-term issue if China doesn't step up its welfare benefits. 'Chinese people deserve a better life," he said. Facing external threats, China wants to be more self-reliant One possibility, put forward at the same forum by Liu Qiao, the dean of the business school, would be to change incentives for local government officials, rewarding them for raising consumption or household incomes instead of meeting an economic growth target. He doesn't see that happening nationwide but said it could be tested in a province. 'That would send out a message that China needs a different approach,' he said. Chinese leader Xi Jinping has made transforming the country into a technology superpower a top priority. It's a goal that has gained urgency as the U.S. has tightened restrictions on China's access to high-end semiconductors and other advanced knowhow. Output in high-tech manufacturing is growing quickly, adding to potential overcapacity, just as what happened with the government's encouragement of 'green' technologies such as solar panels and wind turbines. Various industries, including EV makers, have pledged to address the issue, but some local governments are striving to keep money-losing enterprises afloat, reluctant to lose tax revenues and jobs, or to fail to meet economic growth targets. Going forward, the government is calling for more coordination of economic development polices in fields such as artificial intelligence so that not every province champions the same industry. But government moves to counter the impact of higher tariffs tend to support sectors already in overcapacity, and the share of consumption in the economy has fallen in recent years. 'A sustained improvement in household consumption will require greater reform ambition,' the World Bank said in its most recent update on China's economy."
